Safety of Taffix reaffirmed
A leading biopharma company and makers of rapid delivery innovation for life-saving medicines - Nasus Pharma - stands behind its nasal spray, Taffix, reassuring the public of its safety and clinical efficacy. Taffix is built on an existing, proven, medical technology, which is already used in many nasal sprays to combat allergies and the common cold viruses.
Dr Dalia Megiddo, co-founder and chief executive officer of Nasus Pharma, stresses: “Taffix is safe and legally marketed in Europe under CE certification as an over-the-counter general medical device product. It is indicated for the use as a safe, protective mechanical barrier against allergens and viruses within the nasal cavity. Manufactured to the strictest of compliance to all regulatory requirements, Taffix has been used by hundreds of thousands of people across the globe and there have been no health or safety concerns reported in relation to its intended conditions of use.
“Confusion has arisen because the Spanish authorities have taken the view that Taffix should be classified as a Medical Device Class III and not Class I product in Spain. This opinion is not consistent with the classification position of the countries within the European Union (EU) and of every country in the world that has approved Taffix. While we respect the Spanish Ministry position, we do not agree with it. Guided by all the experts we work with; we do not accept the validity of the Spanish Agency’s assessment and will be working closely with the authority on this matter.”
Dr Dalia Megiddo adds: “As a company, safety and clinical efficacy is best practice which is why we have tested Taffix thoroughly. ”
Sold in over 20 countries across Europe, America, Asia and Africa, Taffix is not a replacement for masks, it is an additional layer of self-care protection, particularly useful in high-risk settings such as any enclosed space.
March 17th 2021
Nasus Pharma Ltd.
You’re good to go
Taffix is a scientifically proven nasal spray that creates a hostile microenvironment in the nose where up to 97% of airborne viruses can’t survive.
Taffix does not replace use of masks and all other measures recommended by health authorities
Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix™ Intranasal Antiviral Protection in Super Spread Event
Tel Aviv , Israel, October 13, 2020
VIEW FULL PR
The Taffix™ (Powder) Spray Device is indicated for use against allergens and viruses within the nasal cavity.
"We were impressed by the ability of Taffix™ to effectively reduce the amount of live virus. This innovative approach could provide a valuable protective measure that would help reduce the spread of the virus and complement worldwide efforts to find a drug or a vaccine”.
- Barbara Mann
Ph.D. Associate Professor, Medicine: Infectious Diseases and International Health at the University of Virginia
University of Virginia Study
In a series of laboratory in vitro studies mimicking the nasal cavity that were performed at the University of Virginia with cells cultures, Taffix™ gel was found to be highly effective and consistently reduced infection* by 99.9%.
The gel layer produced by Taffix™ powder after administration of a clinical equivalent amount, effectively blocked the infections.
How It Works
Taffix’s creates a hostile microenvironment in the nose where up to 97% of airborne viruses can’t survive.
Protect the nose
Your nose is the primary route of infection for all airborne viruses. It has a pH of 6.5 which viruses just love.
The spray creates an ultra-thin gel in your nasal cavity that provides protection for 5 hours.
The ultra-thin gel lowers the nasal cavity’s pH to 3.5, where up to 97% of viruses are rendered ineffective.